Abstract | CONTEXT: OBJECTIVE: TYPE OF STUDY: Retrospective. SETTING: Division of Nuclear Medicine, Universidade Estadual de Campinas (Unicamp). METHODS: RESULTS: All patients showed good uptake of 153Sm-EDTMP by bone metastases. Among the patients with prostate cancer, intermediate or good response to therapy occurred in 80.6% (25 patients) and poor response in 19.4% (6). Among the patients with breast cancer, 85% (17) showed intermediate or good response to therapy while 15% (3) showed poor response. All three patients with lung cancer showed poor response to treatment. The lung hemangioendothelioma and unknown primary lesion patients showed intermediate response to treatment; the osteosarcoma and parathyroid adenocarcinoma patients showed good response to treatment. No significant myelotoxicity occurred. DISCUSSION:
Pain control is important for improving the quality of life of patients with advanced cancers. The mechanism by which pain is relieved with the use of radionuclides is still not yet completely understood, however, the treatment is simple and provides a low risk of mielotoxicity. CONCLUSION:
|
Authors | Elba Cristina Sá de Camargo Etchebehere, Carlos Araújo Cunha Pereira Neto, Mariana Cunha Lopes de Lima, Allan de Oliveira Santos, Celso Darío Ramos, Cleide Maria Silva, Edwaldo Eduardo Camargo |
Journal | Sao Paulo medical journal = Revista paulista de medicina
(Sao Paulo Med J)
Vol. 122
Issue 5
Pg. 208-12
(Sep 02 2004)
ISSN: 1516-3180 [Print] Brazil |
PMID | 15558143
(Publication Type: Evaluation Study, Journal Article)
|
Chemical References |
- Analgesics, Non-Narcotic
- Organometallic Compounds
- Organophosphorus Compounds
- samarium Sm-153 lexidronam
|
Topics |
- Analgesics, Non-Narcotic
(administration & dosage, adverse effects, therapeutic use)
- Bone Neoplasms
(secondary)
- Dose-Response Relationship, Radiation
- Epidemiologic Methods
- Female
- Humans
- Male
- Middle Aged
- Organometallic Compounds
(administration & dosage, adverse effects, therapeutic use)
- Organophosphorus Compounds
(administration & dosage, adverse effects, therapeutic use)
- Osteosarcoma
(secondary)
- Pain
(etiology, radiotherapy)
- Pain Measurement
|